Cipher Pharmaceuticals (TSE:CPH) Trading Down 18.7% – Here’s What Happened

Posted by Donald Scott on Aug 12th, 2026

Cipher Pharmaceuticals Inc. (TSE:CPH – Get Free Report) (NASDAQ:CPHR) was down 18.7% on Wednesday . The company traded as low as C$13.96 and last traded at C$14.60. Approximately 235,912 shares traded hands during mid-day trading, an increase of 768% from the average daily volume of 27,167 shares. The stock had previously closed at C$17.95.

Wall Street Analysts Forecast Growth

Separately, Canaccord Genuity Group set a C$17.00 price objective on shares of Cipher Pharmaceuticals and gave the stock a “hold” rating in a report on Tuesday, May 12th. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of C$17.00.

Check Out Our Latest Research Report on Cipher Pharmaceuticals

Cipher Pharmaceuticals Stock Performance

The company has a quick ratio of 2.67, a current ratio of 1.25 and a debt-to-equity ratio of 0.32. The stock has a 50 day simple moving average of C$16.68 and a 200 day simple moving average of C$16.61. The company has a market capitalization of C$370.20 million, a price-to-earnings ratio of 12.25 and a beta of 1.15.

Cipher Pharmaceuticals (TSE:CPH – Get Free Report) (NASDAQ:CPHR) last announced its quarterly earnings results on Tuesday, August 11th. The company reported C$0.21 earnings per share for the quarter. The business had revenue of C$17.14 million for the quarter. Cipher Pharmaceuticals had a return on equity of 25.69% and a net margin of 60.82%. As a group, analysts anticipate that Cipher Pharmaceuticals Inc. will post 1.2907348 earnings per share for the current fiscal year.

Cipher Pharmaceuticals Company Profile

(Get Free Report)

Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.